Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Conditions
Interventions
eribulin mesylate
pemetrexed
+1 more
Locations
18
United States
Tucson, Arizona, United States
Denver, Colorado, United States
Fort Myers, Florida, United States
Mount Holly, New Jersey, United States
Nashville, Tennessee, United States
Tacoma, Washington, United States
Start Date
June 10, 2010
Primary Completion Date
December 31, 2012
Completion Date
March 18, 2015
Last Updated
June 22, 2023
NCT05671510
NCT03340506
NCT07485114
NCT06066138
NCT05098132
NCT04977453
Lead Sponsor
Eisai Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions